Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Core Insights - Virax Biolabs Group Limited has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies on ViraxImmune™, focusing on immune profiling in individuals with post-viral syndromes, particularly long COVID [1][2][3] - The collaboration aims to generate clinical data that will support regulatory submissions and potential commercial rollout of ViraxImmune™ [2][3] - The partnership is part of Virax's strategy to prepare for a pre-submission meeting with the FDA to discuss the regulatory pathway for ViraxImmune™ in PASC [3][4] Company Overview - Virax Biolabs is an innovative biotechnology company focused on immune response detection and diagnostics, particularly in viral diseases [5] - The company is developing T cell-based test technologies aimed at providing an immunology profiling platform, which is crucial for diagnosing post-viral syndromes like long COVID [5] Collaboration Significance - Partnering with Emory University, a leading institution in immunology and clinical research, is seen as a critical step in validating ViraxImmune™ in real-world patient populations [4][7] - The collaboration is expected to advance Virax's U.S. market entry strategy and create long-term value for shareholders [4]